Provided by Tiger Trade Technology Pte. Ltd.

Apollomics Inc

24.33
+0.75683.21%
Post-market: 24.330.00000.00%19:30 EDT
Volume:6K
Turnover:148.10K
Market Cap:53.42M
PE:-3.21
High:24.59
Open:22.93
Low:22.93
Close:23.57
52wk High:42.12
52wk Low:3.66
Shares:2.20M
Float Shares:634.70K
Volume Ratio:0.27
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.5700
EPS(LYR):-7.5700
ROE:-1305.37%
ROA:-57.61%
PB:-16.76
PE(LYR):-3.21

Loading ...

Company Profile

Company Name:
Apollomics Inc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
14
Office Location:
989 East Hillsdale Blvd.,Suite 220,Foster City,California,United States
Zip Code:
94404
Fax:
650 288 1674
Introduction:
Apollomics, Inc., a biopharmaceutical company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China; and Southbank, Australia.

Directors

Name
Position
Hung Wen Chen
Chairman of the Board and Chief Executive Officer and Director
Chen, Hong Jung
Independent Director
Hsien Shu Tsai
Independent Director
Hung Hsien Yen
Independent Director
Ya Chi Huang
Independent Director
Yi Kuei Chen
Chief Operating Officer and Director

Shareholders

Name
Position
Hung Wen Chen
Chairman of the Board and Chief Executive Officer and Director
Yi Kuei Chen
Chief Operating Officer and Director
Peter Lin
Chief Financial Officer